Summary & Overview
HCPCS Q0175: Perphenazine 4 mg Oral Anti-Emetic for Chemotherapy
HCPCS Level II code Q0175 designates perphenazine 4 mg oral as an FDA-approved anti-emetic used as a therapeutic substitute for an IV anti-emetic during chemotherapy, not to exceed a 48-hour regimen. Nationally, this code matters because it standardizes billing for an oral alternative to IV anti-emetic therapy in oncology infusion settings, affecting claims processing, site-of-service billing, and coverage determinations for supportive cancer care. Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what the code represents clinically and operationally, which sites of service typically use it, and which major payers commonly address coverage for oral anti-emetic substitutes. The report summarizes typical billing context and service line placement, notes common modifiers when available, and highlights where input data is not provided. This publication provides benchmarks and policy-relevant context for billing teams, revenue cycle managers, and oncology practice administrators seeking clarity on coding and payer considerations for oral anti-emetic therapy in the chemotherapy setting.
Billing Code Overview
HCPCS Level II code Q0175 represents Perphenazine, 4 mg, oral, an FDA-approved prescription anti-emetic intended for use as a complete therapeutic substitute for an intravenous anti-emetic at the time of chemotherapy treatment. The code describes a medication-based supportive oncology service administered orally to prevent or treat chemotherapy-induced nausea and vomiting.
Service Type: Oral anti-emetic medication for chemotherapy support
Typical Site of Service: Oncology infusion centers, outpatient chemotherapy clinics, and other ambulatory care settings where chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing moderately to highly emetogenic chemotherapy who presents to an outpatient oncology infusion center. The oncology nurse documents that the patient has nausea and vomiting risk associated with the planned chemotherapy regimen. The prescribing oncologist orders an oral anti-emetic agent to be administered at the time of chemotherapy as a complete therapeutic substitute for an IV anti-emetic when IV access is limited, when oral administration is preferred, or to simplify care for a short-course regimen. Pharmacy dispenses Q0175 (perphenazine, 4 mg, oral) with instructions not to exceed a 48-hour dosage regimen. The medication is administered or provided in the infusion suite or clinic reception area; nursing documents administration time, route (oral), dose, and patient response. Billing staff applies the HCPCS Level II code Q0175 on the facility claim. Clinical workflow steps: prescription review by oncology pharmacist, verification of chemotherapy timing and interactions, nursing administration and monitoring during the chemotherapy encounter, documentation in the medical record, and submission of a facility charge using Q0175 with appropriate modifiers and the encounter diagnosis code(s) reflecting chemotherapy-induced nausea and vomiting risk or related diagnosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|